<DOC DOCNO="nw/xinhua/00/chtb_0064@0064@xinhua@nw@en@on">
<TEXT PARTNO="000">
<COREF ID="1" TYPE="IDENT">Huiliang Bai , director of the National Pharmaceutical Management Bureau Office</COREF> says that the areas of pharmaceutical industry in which <COREF ID="0" TYPE="IDENT">China</COREF> encourages foreign businesses to invest are : those that can meet the needs of domestic and foreign markets , upgrade product levels , expand foreign sales , increase exports and foreign currency earnings ; enterprises that can produce medicine that can not be produced by <COREF ID="0" TYPE="IDENT">China</COREF> but is urgently needed ; those that can introduce domestically needed advanced technology to reform old enterprises ; those that can introduce new high level technology , patent technology and products ; and those that bring advanced management experience .
<COREF ID="1" TYPE="IDENT">He</COREF> says that apart from investment , <COREF ID="0" TYPE="IDENT">the Chinese government</COREF> also welcomes cooperation of foreign pharmaceutical enterprises to cooperate with <COREF ID="0" TYPE="IDENT">China</COREF> in other ways , such as compensation trade , licensing trade , third party processing , technology transfer , and joint development of new products .
-LRB- End -RRB-
</TEXT>
</DOC>
